Evaluating real-world COVID-19 vaccine effectiveness using a test-negative case-control design

5Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aim: It is important to assess if clinical trial efficacy translates into real-world effectiveness for COVID-19 vaccines. Materials & methods: We conducted a modified test-negative design (TND) to evaluate the real-world effectiveness of three COVID-19 vaccines. We defined cases in two ways: self-reported COVID-19-positive tests, and self-reported positive tests with ≥1 moderate/severe COVID-19 symptom. Results: Any vaccination was associated with a 95% reduction in subsequently reporting a positive COVID-19 test, and a 71% reduction in reporting a positive test and ≥1 moderate/severe symptom. Conclusion: We observed high effectiveness across all three marketed vaccines, both for self-reported positive COVID-19 tests and moderate/severe COVID-19 symptoms. This innovative TND approach can be implemented in future COVID-19 vaccine and treatment real-world effectiveness studies. Clinicaltrials.gov identifier: NCT04368065. Tweetable abstract Evaluating real-world COVID-19 vaccine effectiveness. #COVID19 #Vaccines #TND #PRO #patientreportedoutcome.

Cite

CITATION STYLE

APA

Reynolds, M. W., Secora, A., Joules, A., Albert, L., Brinkley, E., Kwon, T., … Dreyer, N. A. (2022). Evaluating real-world COVID-19 vaccine effectiveness using a test-negative case-control design. Journal of Comparative Effectiveness Research, 11(16), 1161–1172. https://doi.org/10.2217/cer-2022-0069

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free